83 results about "Corneal neovascularization" patented technology

A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.

The present invention relates to oxygenated ophthalmic topical compositions and methods of administering oxygenated ophthalmic topical compositions. The present invention also encompasses methods for making and administering the oxygenated ophthalmic topical compositions for use in treating or ameliorating pathologic conditions, complications, diseases and symptoms related to hypoxia of the anterior eye structure, including corneal neovascularization (CNV), edema, abrasions, infections, infiltrates, dry eye syndrome, contact lens intolerance; and redness, blurred vision, discomfort, foreign body sensation, photophobia, and irritation.

The invention discloses an eye drop and a preparation method thereof, relating to an eye drop. The invention provides an eye drop with short action time, high purity and relatively good effect and capability of simultaneously playing a role of corneal neovascularization, lymphangiogenesis and cornea inflammation resistance and a preparation method thereof. The eye drop contains the following components by volume percent: 0.1-5% of bovine serum, 5-15% of thickening agent, 1-5% of acid-base regulating solution, 0.5-2% of antibiotics, 5-20% of recombinant protein and the balance of balanced salt solution. The eye drop contains the balanced salt solution, the thickening agent, the bovine serum, the antibiotics, the acid-base regulating solution and the recombinant protein. The preparation method of the eye drop comprises the following steps of: adding the thickening agent, the bovine serum, the antibiotics and the recombinant protein to the balanced salt solution, regulating a pH value by using the acid-base regulating solution and osmotic pressure by using an osmotic pressure buffering agent, and removing bacteria through membrane filtration; or preparing the bovine serum to sterile micropowder, dissolving the bovine serum into the balanced salt solution, regulating the pH value, removing the bacteria through the membrane filtration, and dissolving recombined powder into the solution so as to obtain the eye drop.

The invention relates to eye drops adopting arteannuinum succinate as the raw material for treating corneal neovascularization and a preparation method thereof. The arteannuinum succinate eye drops can be produced by adopting raw materials in the following parts by weight: 0.0096 to 0.0384 parts of arteannuinum succinate, 1.0032 to 12.028 parts of acid component in buffer solution, 0.106 to 18.0477 parts of alkaline component in buffer solution, 1.0 to 35.0 parts of thickener, 2.0 to 4.72 parts of isotonic reagent and 0.01 to 0.02 parts of antiseptics. The preparation method for the eye drops comprises the following steps: dissolving the arteannuinum succinate with NaHCO3, filtering and sterilizing for later use; dissolving appropriate amount of buffer solution, isotonic reagent and thickener into distilled water, sterilizing for 20 minutes with 100 to 120 DEG C high pressure to obtaining treatment fluid, and cooling the treatment fluid to room temperature for stand to by use; preparing the antiseptics with distilled water into high concentration storage solution, filtering, sterilizing and subpackaging for later use; in aseptic condition, adding the arteannuinum succinate into the treatment fluid according to the ratio of adding 16 to 66 Mul of arteannuinum succinate into 100 ml treatment fluid, uniformly blending, and at the same time, adding the antiseptics into the buffer solution according to the ratio of adding 50 to 100 Mul of antiseptics into 100 ml buffer solution, and subpackaging and producing eye drops in different specifications; preferably, the package per bottle is 0.5 ml.

Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity.

The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2/Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using this peptide as an antigen is effective for inhibition of choroid neovascularization, and thereby completed the present invention. More specifically, the present invention provides vaccines for treatment and/or prevention of diseases caused by choroid neovascularization (neovascular maculopathy), which contain a VEGFR-2-derived peptide as an active ingredient.

The invention discloses application of transthyretin (TTR) to the inhibition of ocular neovascularization and belongs to the field of biochemistry, molecular biology and medical science. The application finds out that mammal TTR is given and ocular new blood vessels in STZ (Streptozocin)-induced diabetes mellitus rat and mouse models are obviously reduced. An in-vivo experiment model of ocular neovascularization and brain neovascularization verifies that the TTR has the effect of inhibiting the neovascularization and a result shows that the TTR acts on ocular capillary endothelial cells and can be used for effectively inhibiting the formation of 90 percent of the blood vessels; and when the TTR acts in the rat and mouse models, high up to 90% of neovascularization can be effectively inhibited.

The invention belongs to the field of biomedical-material-and-medical crossover, and particularly discloses an application of celastrol to preparing an eye drop preparation for inhibiting alkali burn corneal neovascularization and promoting corneal alkali burn healing. 7.04 g-67.55 g of triblock copolymer PEG-PCL-PEi and 0.68 g-2.11 g of the celastrol are weighed and jointly dissolved into a mixed solvent prepared from methyl alcohol and acetonitrile in the volume ratio of 1:(1-3); under ultrasonic stirring, mixed liquid is dropwise added into dissolving equivalent amount of injection water, an organic solvent is removed in a vacuum-distillation mode, dissociative celastrol is removed in an ultra-filtration mode, a medicine loading polymeric micelle is obtained, injection water is additionally added till the volume is fixed to be 100 mL, and eye drop is obtained. According to the celastrol, the PEG-PCL-PEi firstly serves as a carrier, and loads the celastrol, the eye drop is prepared, the medicine feeding mode of eye-surface dropping is achieved, and the celastrol has the milepost-type significance.

Particles encapsulating a glucocorticoid such as dexamethasone sodium phosphate (DSP) into a matrix such as biodegradable poly(lactic-coglycolic acid) (PLGA) which is densely coated with hydrophilic polymer such as PEG or PLURONIC® F127, exhibit sustained release of DSP for up to 7 days in vitro. These nanoparticles can be used to prevent corneal graft rejection or corneal neovascularization.

There are provided inter alia methods and compounds useful for decreasing choroidal neovascularization in a subject in need thereof.

The invention discloses a VEGF (Vascular Endothelial Growth Factor) resistant antibody belonging to the fields of biotechnology and immunology and application of the VEGF resistant antibody. Amino acid sequences of three complementary determining regions (CDR) of heavy chain variable regions of the antibody are respectively shown as SED ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3; the amino acid sequences of the three complementary determining regions of light chain variable regions of the antibody are respectively shown as SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. According to the VEGF resistant humanized antibody, specific targeting combines with VEGF antigens, and an antibody affinity is 3.11*10<-10>, the binding capacity of the antibody and the antigens is high; the VEGF resistant humanized antibody has a good biological activity and can inhibit cell proliferation of vascular endothelial cells, obviously inhibit tumor growth, and effectively inhibit the growth of corneal neovascularization, and can be used for preparing targeted medicines of specific targeting VEGF antigens or angiogenesis inhibiting medicines.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The present disclosure provides pharmaceutical compositions and methods thereof for the prevention or treatment of ocular neovascularization, such as AMD, in a subject, by administering to the subject a pharmaceutical composition comprising a rAAV vector having a nucleic acid sequence that encodes an anti-VEGF agent.

The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.

The invention discloses hydrogen-containing eye drops and a preparation method and application thereof. The hydrogen-containing eye drops comprise injection water and 0.5-1.3 mmol/l hydrogen. The preparation method of the hydrogen-containing eye drops includes: introducing hydrogen into the injection water in the tightness condition; after the hydrogen is dissolved and saturate in the injection water, stopping hydrogen introduction to obtain hydrogen-containing solution; filling and sealing to obtain the hydrogen-containing eye drops. The hydrogen-containing eye drops are applied to treating corneal neovascularization. The hydrogen-containing eye drops have the advantages that expression of an important VEGF (vascular endothelial growth factor) in corneal neovascularization growth factors is decreased by lowering inflammatory response factor interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha); secretion of MMPs (matrix metalloproteinases) can be inhibited, and accordingly less corneal neovascularization occurs, keratitis response is lessened, and great benefit is brought to patients with corneal neovascularization.

Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.